Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Fang C, Stavrou E, Schmaier AA, Grobe N, Morris M, Chen A, Nieman MT, Adams GN, LaRusch G, Zhou Y, Bilodeau ML, Mahdi F, Warnock M, Schmaier AH.

Blood. 2013 Apr 11;121(15):3023-32. doi: 10.1182/blood-2012-09-459156. Epub 2013 Feb 5. Erratum in: Blood. 2014 Mar 6;123(10):1622.

2.

Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.

Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, Krijanovski Y, Murphey LJ, Jaffa AA, Schmaier AH.

Blood. 2006 Jul 1;108(1):192-9. Epub 2006 Mar 2.

3.

Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.

Stavrou EX, Fang C, Merkulova A, Alhalabi O, Grobe N, Antoniak S, Mackman N, Schmaier AH.

Blood. 2015 Jan 22;125(4):710-9. doi: 10.1182/blood-2014-01-550285. Epub 2014 Oct 22.

4.

Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis.

Momi S, Caracchini R, Falcinelli E, Evangelista S, Gresele P.

Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):820-9. doi: 10.1161/ATVBAHA.114.303290. Epub 2014 Feb 20.

5.

Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart.

Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP.

Hypertension. 2005 Oct;46(4):937-42. Epub 2005 Sep 12.

6.

The Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling.

Shen B, Harrison-Bernard LM, Fuller AJ, Vanderpool V, Saifudeen Z, El-Dahr SS.

J Am Soc Nephrol. 2007 Apr;18(4):1140-9. Epub 2007 Mar 7.

7.

The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets.

Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M, Santos RA.

Mol Med. 2008 Jan-Feb;14(1-2):28-35.

8.

Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas.

Peiró C, Vallejo S, Gembardt F, Palacios E, Novella S, Azcutia V, Rodríguez-Mañas L, Hermenegildo C, Sánchez-Ferrer CF, Walther T.

J Physiol. 2013 May 1;591(Pt 9):2275-85. doi: 10.1113/jphysiol.2013.251413. Epub 2013 Mar 4.

9.

Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function.

da Costa Gonçalves AC, Leite R, Fraga-Silva RA, Pinheiro SV, Reis AB, Reis FM, Touyz RM, Webb RC, Alenina N, Bader M, Santos RA.

Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2588-96. Epub 2007 Jul 6.

10.

Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling.

Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M.

Hypertension. 2012 Jul;60(1):137-44. doi: 10.1161/HYPERTENSIONAHA.112.191452. Epub 2012 Jun 4.

11.

Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.

De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G.

Eur J Pharmacol. 2005 Jun 15;516(3):253-9.

PMID:
15963975
12.
13.

The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice.

Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA.

J Cardiovasc Pharmacol. 2005 Sep;46(3):274-9.

PMID:
16116331
14.

Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.

Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T.

Hypertension. 2002 Oct;40(4):521-7.

15.

Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation.

Chan HC, Ke LY, Chu CS, Lee AS, Shen MY, Cruz MA, Hsu JF, Cheng KH, Chan HC, Lu J, Lai WT, Sawamura T, Sheu SH, Yen JH, Chen CH.

Blood. 2013 Nov 21;122(22):3632-41. doi: 10.1182/blood-2013-05-504639. Epub 2013 Sep 12.

16.

Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis.

Zhang S, Zhang S, Hu L, Zhai L, Xue R, Ye J, Chen L, Cheng G, Mruk J, Kunapuli SP, Ding Z.

Circulation. 2015 Mar 31;131(13):1160-70. doi: 10.1161/CIRCULATIONAHA.114.013743. Epub 2015 Feb 17.

PMID:
25825396
17.

Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.

Li W, Gigante A, Perez-Perez MJ, Yue H, Hirano M, McIntyre TM, Silverstein RL.

Circ Res. 2014 Dec 5;115(12):997-1006. doi: 10.1161/CIRCRESAHA.115.304591. Epub 2014 Oct 6.

18.

Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats.

Kramkowski K, Mogielnicki A, Leszczynska A, Buczko W.

J Physiol Pharmacol. 2010 Jun;61(3):317-24.

19.

GDF-15 prevents platelet integrin activation and thrombus formation.

Rossaint J, Vestweber D, Zarbock A.

J Thromb Haemost. 2013 Feb;11(2):335-44. doi: 10.1111/jth.12100.

PMID:
23231375
20.

Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats.

Carvalho MB, Duarte FV, Faria-Silva R, Fauler B, da Mata Machado LT, de Paula RD, Campagnole-Santos MJ, Santos RA.

Hypertension. 2007 Oct;50(4):762-7. Epub 2007 Jul 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk